News

03 Mar 2017

ReproCELL Europe's CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research

ReproCELL Europe's CEO, Dr David Bunton presented at the recent NC3Rs meeting on the use of human tissues in cancer research. The conference considered the potential for human tissue models to help reduce clinical drug attrition and provide more relevant models of cancer using techniques such as 3D models, PDX systems and precision-cut tumour slices.
Read More >>

14 Feb 2017

ReproCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan

ReproCELL Inc. (Japan)s CEO Dr Chikafumi Yokoyama had the honour of meeting with Fiona Hyslop, Cabinet Secretary for Culture, Tourism and External Affairs for the Scottish Government, during her visit to the Scottish Enterprise Tokyo office, today (14 February 2017).
Read More >>

07 Feb 2017

Scottish Enterprise Association Honours ReproCELL with Annual Awards Nomination

Scottish Enterprise Association Honours ReproCELL with Annual Awards Nomination
Read More >>

20 Jan 2017

Job vacancy: Clinical Alliances Manager

We wish to recruit a Clinical Alliances Manager to grow and manage our clinical network of hospitals, tissue banks and organ procurement organisations. The Clinical Alliances Manager ensures that sufficient donations of tissue are received to support ReproCELLs research on new medicines and to ensure compliance with relevant legal and regulatory requirements.
Read More >>

1 2 3 4 >>

Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development

16/11/2016

Today, ReproCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. (headquarters: Naka-ku, Yokohama; CEO: Kazuyoshi Miyajima; henceforth, FANCL) for the development of a 3D model system derived from human iPS cells.

1. Details of entrustment contract

 

As per this contract, FANCL will develop a multi-component cell culture model system derived from human iPS cells in collaboration with ReproCELL and employ the technology to focus on anti-aging drug development. FANCL researches, develops, manufactures, and sells cosmetics and nutritional supplements; in the future, FANCL will use the cell technology to advance its basic research and product development.

 

Human iPS cells hold great promise not only for regenerative medicine, but as a tool for product development applicable to a variety of fields. A key strategy of ReproCELL is to apply the accumulated corporate human iPS cell know-how to development innovative tools for use in a variety of medical and other business applications.


2. Schedule

 

Date of contract formation and business start date: November 16, 2016

 

3. Partner overview
 

(1) Name FANCL Corp.
(2) Location 89-1 Yamashita-chou, Naka-ku, Yokohama
(3) Name & position of representative Representative Director and President/CEO Kazuyoshi Miyajima
(4) Business activities Research, development, manufacture, and sales of cosmetics, supplements, and health foods
(5) Capital Stock 10,795,000,000 yen
(6) Date founded August 18, 1981
(7) Major stockholders and percentage of stock held KI Corp. (13.05%)
Kenji Ikemori (8.76%)


End.

Live chat by BoldChat